ABSTRACT GUIDELINES – 21st International Headache Congress (IHC) 2023

Please review this document before finalising your abstract submission.

ABSTRACT TOPICS

Abstracts are accepted under the following topics.

- BIG DATA
- CLUSTER HEADACHE AND OTHER TRIGEMINAL AUTONOMIC CEPHALALGIAS
- COMORBIDITY OF PRIMARY HEADACHES
- GENETICS AND BIOMARKERS OF HEADACHE DISORDERS
- HEADACHE CLASSIFICATION
- HEADACHE DISORDERS IN CHILDREN AND ADOLESCENTS
- HEADACHE EDUCATION FOR CLINICIANS AND PATIENTS
- HEADACHE EPIDEMIOLOGY, OUTCOMES AND BURDEN
- HEADACHE AND GENDER
- HEADACHE IN HISTORY AND THE ARTS
- HEADACHE PATHOPHYSIOLOGY – BASIC SCIENCE
- HEADACHE PATHOPHYSIOLOGY – IMAGING AND NEUROPHYSIOLOGY
- MIGRAINE ACUTE THERAPY
- MIGRAINE PREVENTIVE THERAPY
- NEUROMODULATION FOR HEADACHE
- OTHER PRIMARY HEADACHE DISORDERS
- OTHER SECONDARY HEADACHE DISORDERS
- POST-TRAUMATIC HEADACHE
- PSYCHOLOGICAL AND BEHAVIOURAL FACTORS AND MANAGEMENT
- TENSION-TYPE HEADACHE
- TRIGEMINAL NEURALGIA AND OTHER CRANIAL NEUROPATHIES
- OTHER

IMPORTANT DATES

- Submissions accepted from: 18 November 2022
- Submission deadline: 10 May 2023 at 23:59 (GMT/UK time)
- Abstracts Review: May 2023
- Late breaking abstract submission opens – 31 May 2023
- Late breaking abstract submission closes – 15 June 2023

Abstracts received after the deadline will not be accepted.

GENERAL

1. Abstracts can only be submitted online via the abstract submission portal that can be found in the section “ABSTRACTS” on the official congress website: www.IHC2023.org
2. Abstracts must be submitted in English.
DEFINITIONS
- Submitting author: person who submits the abstract
- Presenting author: person who will physically present the abstract at the congress and who is marked as the presenter in the programme.

TRAINEE'S EXCELLENCE TOURNAMENT
The IHS Juniors Group will select the best abstracts submitted by Trainees for inclusion within the Excellence Tournament.

The congress attendees will vote on their favourite presentation within the tournament, the winner will receive a cash prize. If you would like your submission to be considered for this session please tick the appropriate box within the submission process.

Please also complete the Junior Member Verification Form accessed [here](https://ihs-headache.org/en/about-ihs/special-interest-groups/juniors-group/) and send to the organisers IHC2023@mci-group.com along with the abstract submission number.

Only abstracts that have a completed Verification Form will be considered for inclusion within the Tournament. Further details on the Juniors Group and the Trainees Excellence Tournament can be found at the following link – [https://ihs-headache.org/en/about-ihs/special-interest-groups/juniors-group/](https://ihs-headache.org/en/about-ihs/special-interest-groups/juniors-group/)

PUBLICATION AND EMBARGO
- All abstracts accepted for IHC 2023 will be published in the following places:
  - Cephalalgia journal – September 2023
  - IHC 2023 app and digital platform
- All abstracts accepted for IHC 2023 will be under embargo until 09:00 (Republic of Korea time) on the morning of Thursday 14 September 2023

RULES
Failure to observe these guidelines may result in disqualification.

1. An abstract can be submitted to the IHC 2023 if it has been presented or published at a national meeting however this must be stated during submission. Submissions presented at international congresses previously will not be accepted. In addition to this the abstract results must not have been previously published within a journal.

2. The abstract presenter will need to be registered to do so, whether the presentation will be in person or online.

3. The correct topic must be selected to ensure correct scoring. The content of the abstract must be topic related. The Scientific Committee reserve the right to re-categorize an abstract.

4. Abstracts must contain data and meet international ethical standards.

5. Abbreviations should be defined.
6. Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body of the text.

7. An abstract cannot be accepted if the conflict of interest disclosure has not been completed on the submission form. If the presenter or one of the co-authors has a conflict of interest, this must be clearly stated.

8. The abstract cannot contain more than 700 words – blank spaces, punctuation as well as author names, author affiliations and titles are included in the character count. The title has a limit of 50 words.

9. The abstract must be structured into the following sections: Objective; Methods; Results; Conclusion.

10. One table can be included, with the following restrictions:
    Max number of columns: 10
    Max number of rows: 10

11. Please note that tables may significantly reduce the number of available characters.

12. If you have successfully submitted your abstract, you will receive a confirmation number. If no confirmation number is received, the abstract cannot be considered as successfully submitted and accepted.

13. Abstracts fulfilling all criteria can be saved in “FINAL SUBMISSION” status. Only abstracts in “FINAL SUBMISSION” status will be considered as successfully submitted and accepted.

14. If you leave the system without saving the abstract all data is lost. The submitted/draft abstracts cannot be edited after the submission deadline (Wednesday 10 May 2023, 23:59 GMT/UK time).

15. Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are possible after the submission deadline. The abstract will be reproduced exactly as submitted. No proof reading will be completed.

16. If you need to withdraw your abstract, a written statement reflecting the reasons for this decision must be sent to: IHC2023@mci-group.com, no later than 24 May 2023.

**AFTER THE SUBMISSION**

1. The reviewers will judge the abstracts according to the relevance to IHC 2023. They will assess the standard of English, objectivity of statements, description of the work, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.

2. The submitting author will be notified during the week commencing 26 June 2023 whether the abstract has been accepted. Notifications will be sent via email to the email address provided during submission. It is the authors’ responsibility to ensure that emails from IHC 2023 can reach them. Within the notification authors will be informed of the date, time and form of the presentation.
PUBLICATION POLICY
All abstracts accepted for presentation (oral or poster) will be published in digital format within the official congress app. The abstracts for IHC 2023 will also be published in Cephalalgia. All abstracts accepted for presentation at IHC 2023 will be included within the event app.

PRESENTATION OF ABSTRACTS
1. We understand that not all submitters may be able to attend IHC 2023 Congress in Seoul in person. We do not want to hinder the submission of abstracts. There will be funding available for some abstract presenters. Please do submit your abstract for review. The opportunities to either attend in Seoul to present or to deliver your presentation online will be discussed following the review process.
2. During your submission, please indicate your preference of presentation format – poster, oral or e-poster.
3. Oral presentations will be given further information on length of lecture and presentation details closer to the meeting.
4. Full presentation guidelines will be included in the acceptance letter and posted on the congress website.

PROBLEMS SUBMITTING?
If you experience any kind of problem or if you have questions, please do not hesitate to contact the abstract management team on the contact details below:

Email: IHC2023@mci-group.com